 |
34 Diseases |  |
3 Trials |
|
3 Trials |  |
49 News |  |
- | Trial initiation date, Trial primary completion date: Human Models of Selective Insulin Resistance: Pancreatic Clamp (clinicaltrials.gov) - Sep 20, 2024
P1, N=36, Not yet recruiting, Sponsor: Columbia University
Initiation date: Sep 2024 --> Dec 2024 | Trial primary completion date: Aug 2026 --> Dec 2026
- | New P1 trial: Human Models of Selective Insulin Resistance: Pancreatic Clamp (clinicaltrials.gov) - Aug 15, 2024
P1, N=36, Not yet recruiting, Sponsor: Columbia University
- | New P3 trial: Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children (clinicaltrials.gov) - Oct 25, 2023
P3, N=50, Recruiting, Sponsor: Northwell Health
- | Zomacton (somatropin) / Ferring
Trial completion date, Trial primary completion date, Combination therapy: ZomaTrip: A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height (clinicaltrials.gov) - Jul 31, 2023
P4, N=44, Active, not recruiting, Sponsor: Belgian Study Group for Pediatric Endocrinology
Initiation date: Sep 2024 --> Dec 2024 | Trial primary completion date: Aug 2026 --> Dec 2026 Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- | Zomacton (somatropin) / Ferring
Journal: Investigating Thermally Induced Aggregation of Somatropin- New Insights Using Orthogonal Techniques. (Pubmed Central) - Mar 25, 2023
Smaller elongated aggregates are formed in the first step, possibly initiated by partly unfolded species. In the second step, occurring during longer heating, the smaller aggregates assemble into larger aggregates with more complex structures.
- | Journal: Lonapegsomatropin (Skytrofa) for growth hormone deficiency. (Pubmed Central) - Feb 23, 2022
In the second step, occurring during longer heating, the smaller aggregates assemble into larger aggregates with more complex structures. No abstract available
- || Zomacton (somatropin) / Ferring
Elite HRT Publishes Information on Zomacton https://t.co/MflSxY38Lx (Twitter) - Oct 11, 2021
- || Zomacton (somatropin) / Ferring
We used #zomacton faithfully for the last 7 months with no plausible results! We have spent over $7000. @ferring should refund my hard earned $7000. This has left my son heartbroken. @thetimes @US_FDA @FDA_Drug_Info @ferring please contact me! #parent #help (Twitter) - Nov 20, 2020
- | Zomacton (somatropin) / Ferring
Observational data, Retrospective data, Journal: Needle-Free and Needle-Based Growth Hormone Therapy in Children: A Pooled Analysis of Three Long-Term Observational Studies. (Pubmed Central) - Aug 3, 2019
Real-life data show that treatment with Zomacton® improves auxological outcome parameters without new safety concerns. NF administration of GH represents a useful alternative to NI in children with growth disorders.
- | Zomacton (somatropin) / Ferring
Journal: Improved adherence and growth outcomes with jet-delivered growth hormone. (Pubmed Central) - Jun 23, 2019
MPHSDS - HTSDS showed a similar significant improvement at 3 years in adherent patients only (p = 0.0043). Conclusions Patients adherent to JrGH demonstrate significant growth improvement compared to baseline over 3 years.
- Zomacton (somatropin) / Ferring
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Adherence: RAZANT: Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome (clinicaltrials.gov) - Dec 13, 2018
P=N/A, N=4, Terminated, Sponsor: Ferring Pharmaceuticals
Conclusions Patients adherent to JrGH demonstrate significant growth improvement compared to baseline over 3 years. N=700 --> 4 | Trial completion date: Sep 2022 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2022 --> Oct 2018; Insufficient, delayed recruitment of participants
- ||| Zomacton (somatropin) / Ferring
Enrollment open, Adherence: RAZANT: Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome (clinicaltrials.gov) - May 31, 2018
P=N/A, N=700, Recruiting, Sponsor: Ferring Pharmaceuticals
N=700 --> 4 | Trial completion date: Sep 2022 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2022 --> Oct 2018; Insufficient, delayed recruitment of participants Not yet recruiting --> Recruiting
- || Zomacton (somatropin) / Ferring
Phase classification, Adherence: RAZANT: Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome (clinicaltrials.gov) - Mar 27, 2018
P, N=700, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P
- || Zomacton (somatropin) / Ferring
Trial initiation date, Adherence: RAZANT: Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=700, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
Phase classification: P=N/A --> P Initiation date: Feb 2018 --> Mar 2018
- ||| Zomacton (somatropin) / Ferring
New trial, Adherence: RAZANT: Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome (clinicaltrials.gov) - Sep 7, 2017
P=N/A, N=700, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- | Zomacton (somatropin) / Ferring
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: ZomaTrip: A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height (clinicaltrials.gov) - Aug 24, 2017
P4, N=44, Active, not recruiting, Sponsor: Belgian Study Group for Pediatric Endocrinology
Initiation date: Feb 2018 --> Mar 2018 Recruiting --> Active, not recruiting | N=30 --> 44 | Trial primary completion date: Jan 2017 --> Jan 2023
- ||| Zomacton (somatropin) / Ferring
Trial completion, Enrollment change, Trial primary completion date: Online Surveillance of Treatment of Children With Growth Hormone Deficiency With ZOMACTON (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=1086, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting | N=30 --> 44 | Trial primary completion date: Jan 2017 --> Jan 2023 Enrolling by invitation --> Completed | N=873 --> 1086 | Trial primary completion date: Dec 2017 --> May 2016
- || Zomacton (somatropin) / Ferring
Enrollment change, Trial primary completion date: Online Surveillance of Treatment of Children With Growth Hormone Deficiency With ZOMACTON (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=873, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
Enrolling by invitation --> Completed | N=873 --> 1086 | Trial primary completion date: Dec 2017 --> May 2016 N=400 --> 873 | Trial primary completion date: Dec 2016 --> Dec 2017
- || Zomacton (somatropin) / Ferring
Trial completion, Enrollment change: A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency (clinicaltrials.gov) - May 5, 2015
P3, N=23, Completed, Sponsor: Ferring Pharmaceuticals
N=400 --> 873 | Trial primary completion date: Dec 2016 --> Dec 2017 Enrolling by invitation --> Completed | N=46 --> 23
- Zomacton (somatropin) / Ferring
New P2 trial: Early hGH Treatment of SGA Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae (clinicaltrials.gov) - Dec 29, 2014
P2, N=20, Not yet recruiting, Sponsor: Tel-Aviv Sourasky Medical Center
- Zomacton (somatropin) / Ferring
Enrollment open, Combination therapy: ZomaTrip: A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height (clinicaltrials.gov) - Aug 8, 2014
P4, N=30, Recruiting, Sponsor: Belgian Study Group for Pediatric Endocrinology
Enrolling by invitation --> Completed | N=46 --> 23 Active, not recruiting --> Recruiting
- ||| Zomacton (somatropin) / Ferring
Enrollment open, Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=90, Recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Zomacton (somatropin) / Ferring
New P3 trial: A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency (clinicaltrials.gov) - Jun 26, 2014
P3, N=46, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
- || Zomacton (somatropin) / Ferring
Trial initiation date, Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=90, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Jun 2014
- ||| Zomacton (somatropin) / Ferring
Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (clinicaltrials.gov) - Dec 19, 2013
P=N/A, N=90, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- Zomacton (somatropin) / Ferring
Trial withdrawal: Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton® (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=0, Withdrawn, Sponsor: Ferring Pharmaceuticals
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Withdrawn
- Zomacton (somatropin) / Ferring
Enrollment change: Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton® (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=0, Withdrawn, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Withdrawn N=200 --> 0
- ||||||| Zomacton (somatropin) / Ferring
Trial completion: A Study of Zomacton in Children With Growth Hormone Deficiency (clinicaltrials.gov) - Jul 15, 2012
P3, N=165, Completed, Sponsor: Ferring Pharmaceuticals
N=200 --> 0 Active, not recruiting --> Completed
- ||| Zomacton (somatropin) / Ferring
Trial completion, Compliance: Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=87, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed